![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1671852
½É¹æ¼¼µ¿ ½ÃÀå : À¯Çüº°, Ä¡·á¹ýº°, ±â¼úº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°Atrial Fibrillation Market, By Type, By Treatment, By Technology, By End User, By Geography |
½É¹æ¼¼µ¿ ¼¼°è ½ÃÀå ±Ô¸ð´Â 2025³â¿¡ 264¾ï 3,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2025³âºÎÅÍ 2032³â±îÁö CAGR 7.4%·Î ¼ºÀåÇÏ¿© 2032³â¿¡´Â 435¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
º¸°í¼ ¹üÀ§ | º¸°í¼ »ó¼¼ | ||
---|---|---|---|
±âÁØ ¿¬µµ | 2024³â | 2025³â ½ÃÀå ±Ô¸ð | 264¾ï 3,000¸¸ ´Þ·¯ |
½ÇÀû µ¥ÀÌÅÍ | 2020-2024³â | ¿¹Ãø ±â°£ | 2025-2032³â |
¿¹Ãø ±â°£ : 2025-2032³â CAGR | 7.40% | 2032³â °¡Ä¡ ¿¹Ãø | 435¾ï 7,000¸¸ ´Þ·¯ |
½É¹æ¼¼µ¿Àº Àü ¼¼°èÀûÀ¸·Î °¡Àå ÈçÇÑ ºÎÁ¤¸ÆÀ̸ç, Áø´Ü »ç·ÊÀÇ À¯º´·üÀÌ ºü¸£°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ³ëÀÎ Àα¸ÀÇ Áõ°¡, ½ÉÇ÷°üÁúȯ ¹× »ýȰ½À°üº´ÀÇ À¯º´·ü Áõ°¡, ħ½ÀÀû ½ÉÀå ¼ö¼úÀÇ Áõ°¡, Áø´Ü ¹× Ä¡·á ±â±âÀÇ ±â¼ú ¹ßÀüÀº ÀÌ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÀϺÎÀÔ´Ï´Ù. ±×·¯³ª ½É¹æ¼¼µ¿ Áø´Ü ¹× Ä¡·á¿¡ µû¸¥ Ç÷Àü»öÀüÁõ À§Çè°ú °³¹ßµµ»ó±¹ÀÇ ½É¹æ¼¼µ¿¿¡ ´ëÇÑ ÀÎ½Ä ºÎÁ·Àº ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¼¼°è ½É¹æ¼¼µ¿ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ½É¹æ¼¼µ¿ Ãë¾à ³ëÀÎ Àα¸ÀÇ ±ÞÁõ, ºñ¸¸ ¹× °íÇ÷¾Ð À¯º´·ü Áõ°¡, ¾ËÄÚ¿Ã ¹× ´ã¹è ¼Òºñ Áõ°¡, ħ½ÀÀû ½ÉÀå ¼ö¼úÀÇ Áõ°¡ µîÀÔ´Ï´Ù. ±×·¯³ª ½É¹æ¼¼µ¿ Áø´Ü ¹× Ä¡·á¿¡ µû¸¥ Ç÷Àü»öÀüÁõ À§Çè Áõ°¡, ½ÅÈï±¹ÀÇ ½É¹æ¼¼µ¿¿¡ ´ëÇÑ ÀÎ½Ä ºÎÁ·Àº ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. »õ·Î¿î ÀýÁ¦ ±â¼ú °³¹ßÀÇ ¿¬±¸°³¹ß°ú Çõ½ÅÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇÏ´Â ½ºÅ¸Æ®¾÷ÀÇ ÃâÇöÀº ÇâÈÄ ¸î ³â µ¿¾È Å« ±âȸ¸¦ Á¦°øÇÒ °ÍÀÔ´Ï´Ù.
¼¼°èÀÇ ½É¹æ¼¼µ¿ ½ÃÀåÀ» »ó¼¼È÷ ºÐ¼®ÇÏ¿© 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â)ÀÇ ½ÃÀå ±Ô¸ð¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» Á¶»çÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
¶ÇÇÑ, ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
¶ÇÇÑ ½ÃÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.
¼¼°è ½É¹æ¼¼µ¿ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷µéÀ» ȸ»ç ¼Ò°³, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä Æ¯Â¡, ÁÖ¿ä ¼º°ú, Àü·« µîÀÇ ¸Å°³º¯¼ö¸¦ ±â¹ÝÀ¸·Î ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.
ÁÖ¿ä ±â¾÷À¸·Î´Â Pfizer Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Johnson & Johnson, Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, AtriCure, Inc., Sanofi, Bayer AG, Gilead Sciences, Inc., Amgen Inc., Merck & Co., Inc., St. Jude Medical, Inc., Cardiovascular Systems, Inc. µîÀÌ ÀÖ½À´Ï´Ù.
ÀÌ º¸°í¼ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü·«¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
½É¹æ¼¼µ¿ ¼¼°è ½ÃÀå º¸°í¼´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ÁøÀÔÀÚ, À繫 ºÐ¼®°¡ µî ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è ½É¹æ¼¼µ¿ ½ÃÀåÀ» ºÐ¼®ÇÒ ¶§ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.
Global Atrial Fibrillation Market is estimated to be valued at US$ 26.43 Bn in 2025 and is expected to reach US$ 43.57 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.4% from 2025 to 2032.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2024 | Market Size in 2025: | US$ 26.43 Bn |
Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
Forecast Period 2025 to 2032 CAGR: | 7.40% | 2032 Value Projection: | US$ 43.57 Bn |
Atrial fibrillation is the most common cardiac arrhythmia globally and the prevalence of diagnosed cases is growing rapidly. Rising geriatric population, increasing incidence of cardiovascular & lifestyle diseases, growth in invasive cardiac procedures, and technological advancements in diagnostic and treatment devices are some of the key factors fueling the growth of this market. However, risk of thromboembolism associated with atrial fibrillation diagnosis and treatment and lack of awareness about atrial fibrillation in developing countries are expected to hamper market growth.
The key drivers propelling the growth of global atrial fibrillation market are rapid growth in geriatric population who are more susceptible to atrial fibrillation, rising prevalence of obesity and hypertension, increasing consumption of alcohol and tobacco, and growing number of invasive cardiac surgeries. However, high risk of thromboembolism associated with atrial fibrillation diagnosis and treatment and lack of awareness about atrial fibrillation in developing countries are projected to hinder the market growth. Growing research on development of novel ablation technologies and emergence of start-up companies offering innovative solutions present significant opportunities in the coming years.
This report provides in-depth analysis of the global atrial fibrillation market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global atrial fibrillation market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Johnson & Johnson, Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, AtriCure, Inc., Sanofi, Bayer AG, Gilead Sciences, Inc., Amgen Inc., Merck & Co., Inc., St. Jude Medical, Inc., and Cardiovascular Systems, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global atrial fibrillation market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global atrial fibrillation market